|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Molecular Genetics |
Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany (C.B.K., G.R.); and Neurosurgery/Brain Tumor Research, University Hospitals, Basel, Switzerland (A.M.)
3 Address correspondence and reprint requests to Guido Reifenberger, Department of Neuropathology, Heinrich-Heine-University, Moorenstrasse 5, D-40225 Düsseldorf, Germany.
Abstract
In 1997, the PTEN gene (phosphatase and tensin homolog deleted on chromosome 10) was identified as a tumor suppressor gene on the long arm of chromosome 10. Since then, important progress has been made with respect to the understanding of the role of the Pten protein in the normal development of the brain as well as in the molecular pathogenesis of human gliomas. This review summarizes the current state of the art concerning the involvement of aberrant Pten function in the development of different biologic features of malignant gliomas, such as loss of cell-cycle control and uncontrolled cell proliferation, escape from apoptosis, brain invasion, and aberrant neoangiogenesis. Most of the tumor-suppressive properties of Pten are dependent on its lipid phosphatase activity, which inhibits the phosphatidylinositol-3'-kinase (PI3K)/Akt signaling pathway through dephosphorylation of phosphatidylinositol-(3,4,5)-tri phosphate. The additional function of Pten as a dual-specificity protein phosphatase may also play a role in glioma pathogenesis. Besides the wealth of data elucidating the functional roles of Pten, recent studies suggest a diagnostic significance of PTEN gene alterations as a molecular marker for poor prognosis in anaplastic astrocytomas and anaplastic oligodendrogliomas. Furthermore, the possibility of selective targeting of PTEN mutant tumor cells by specific pharmacologic inhibitors of members of the Pten/PI3K/Akt pathway opens up new perspectives for a targeted molecular therapy of malignant gliomas.
This article has been cited by other articles:
|
|
 |
|
  Y. Li, F. Guessous, S. Kwon, M. Kumar, O. Ibidapo, L. Fuller, E. Johnson, B. Lal, I. Hussaini, Y. Bao, et al. PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations Cancer Res., March 15, 2008; 68(6): 1723 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Kuhn, S. M. Chang, P. Y. Wen, T. F. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, K. L. Fink, H. I. Robins, M. Mehta, et al. Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma Clin. Cancer Res., December 15, 2007; 13(24): 7401 - 7406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohgaki and P. Kleihues Genetic Pathways to Primary and Secondary Glioblastoma Am. J. Pathol., May 1, 2007; 170(5): 1445 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Radeff-Huang, T. M. Seasholtz, J. W. Chang, J. M. Smith, C. T. Walsh, and J. H. Brown Tumor Necrosis Factor-{alpha}-stimulated Cell Proliferation Is Mediated through Sphingosine Kinase-dependent Akt Activation and Cyclin D Expression J. Biol. Chem., January 12, 2007; 282(2): 863 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Schaffer, H. Kamino, A. Witkiewicz, J. M. McNiff, and S. J. Orlow Mucocutaneous Neuromas: An Underrecognized Manifestation of PTEN Hamartoma-Tumor Syndrome. Arch Dermatol, May 1, 2006; 142(5): 625 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Edwards, M. Verreault, B. Thiessen, W. H. Dragowska, Y. Hu, J. H.F. Yeung, S. Dedhar, and M. B. Bally Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol. Cancer Ther., March 1, 2006; 5(3): 645 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pore, S. Liu, H.-K. Shu, B. Li, D. Haas-Kogan, D. Stokoe, J. Milanini-Mongiat, G. Pages, D. M. O'Rourke, E. Bernhard, et al. Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1-independent Mechanism Mol. Biol. Cell, November 1, 2004; 15(11): 4841 - 4853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa, P.-L. Di Patre, C. Burkhard, D. Schuler, N. M. Probst-Hensch, P. C. Maiorka, et al. Genetic Pathways to Glioblastoma: A Population-Based Study Cancer Res., October 1, 2004; 64(19): 6892 - 6899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-A. O. Nathan, N. Amirghahari, F. Abreo, X. Rong, G. Caldito, M. L. Jones, H. Zhou, M. Smith, D. Kimberly, and J. Glass Overexpressed eIF4E Is Functionally Active in Surgical Margins of Head and Neck Cancer Patients via Activation of the Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., September 1, 2004; 10(17): 5820 - 5827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Knobbe, J. Reifenberger, B. Blaschke, and G. Reifenberger Hypermethylation and Transcriptional Downregulation of the Carboxyl-Terminal Modulator Protein Gene in Glioblastomas J Natl Cancer Inst, March 17, 2004; 96(6): 483 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Musatov, J. Roberts, A. I. Brooks, J. Pena, S. Betchen, D. W. Pfaff, and M. G. Kaplitt Inhibition of neuronal phenotype by PTEN in PC12 cells PNAS, March 9, 2004; 101(10): 3627 - 3631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van den Boom, M. Wolter, R. Kuick, D. E. Misek, A. S. Youkilis, D. S. Wechsler, C. Sommer, G. Reifenberger, and S. M. Hanash Characterization of Gene Expression Profiles Associated with Glioma Progression Using Oligonucleotide-Based Microarray Analysis and Real-Time Reverse Transcription-Polymerase Chain Reaction Am. J. Pathol., September 1, 2003; 163(3): 1033 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
